Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study

Background Several anti-cytokine therapies were tested in the randomized trials in hospitalized patients with severe acute respiratory syndrome coronavirus 2 infection (COVID-19). Previously, dexamethasone demonstrated a reduction of case-fatality rate in hospitalized patients with respiratory failu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC infectious diseases Jg. 21; H. 1; S. 1277 - 9
Hauptverfasser:	Stanevich, O. V., Fomina, D. S., Bakulin, I. G., Galeev, S. I., Bakin, E. A., Belash, V. A., Kulikov, A. N., Lebedeva, A. A., Lioznov, D. A., Polushin, Yu. S., Shlyk, I. V., Vorobyev, E. A., Vorobyeva, S. V., Surovceva, T. V., Bakulina, N. V., Lysenko, M. A., Moiseev, I. S.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 22.12.2021 BioMed Central Ltd Springer Nature B.V BMC
Schlagworte:	Adult Analysis Anti-cytokine therapy Cardiovascular disease Care and treatment Clinical trials Cohort analysis Cohort Studies Coronaviruses COVID-19 COVID-19 diagnostic tests COVID-19 Drug Treatment Cytokines Dexamethasone Dexamethasone - therapeutic use Dosage and administration Drug dosages Enzyme inhibitors Fatalities Fever Health services Hospital patients Hospitalization Humans Illnesses Infections Infectious Diseases Inhibitor drugs Internal Medicine Janus kinase Kinases Laboratories Medical Microbiology Medicine Medicine & Public Health Mortality Nitriles Oxygen Parasitology Patients Pyrazoles Pyrimidines Research Article Respiratory diseases Respiratory failure Ruxolitinib SARS-CoV-2 Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Steroids Subgroups Therapy Thrombocytopenia Treatment Outcome Tropical Medicine Viral diseases Russia COVID-19 Ruxolitinib SARS-CoV-2 Dexamethasone Anti-cytokine therapy
ISSN:	1471-2334, 1471-2334
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!